Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Clinical Case Studies in Diagnostics and Management of Clostridioides difficile Infection
  • CME
  • CE

Credits Available
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Registered Nurses: 2.0 Nursing contact hours
Pharmacists: 2.0 contact hours (0.2 CEUs)
Released: April 5, 2022 Expiration: April 4, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.
person default
Sahil Khanna, MBBS, MS
Program Director
person default
Teena Chopra, MD, MPH
Paul Feuerstadt, MD, FACG, AGAF
Kevin Garey, PharmD, MS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize epidemiology and classification of C difficile infections, including effective diagnostic strategies and special populations at risk for recurrent C difficile infections
  • Compare treatment options for initial C difficile infections incorporating the latest guideline-based recommendations
  • Contrast new data and recommendations on CDI therapeutic agents for treatment and prevention of recurrence of C difficile infections

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Sahil Khanna, MBBS, MS

Professor of Medicine 
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota

Sahil Khanna, MBBS, MS, has disclosed that he has received consulting fees from Immuron, Jetson, Niche, ProBioTech, and Shire/Takeda and funds for research support from Finch, Pfizer, Rebiotix/Ferring, Seres Therapeutics, and Vedanta.

Faculty

Teena Chopra, MD, MPH

Professor, Infectious Diseases
Wayne State University
Corporate Medical Director
Infection Prevention
Hospital Epidemiology
Detroit Medical Center
Detroit, Michigan

Teena Chopra, MD, MPH, has disclosed that she has received funds for research support from Cepheid and Ferring; consulting fees from Cepheid, Ferring, Merck, Pfizer, and Shionogi; and fees for non-CME services from AbbVie, Cepheid, Ferring, Pfizer, and Shionogi.
Paul Feuerstadt, MD, FACG, AGAF

Assistant Clinical Professor of Medicine
Attending Gastroenterologist

Department of Gastroenterology
Yale University School of Medicine
PACT-Gastroenterology Center
Hamden, Connecticut

Paul Feuerstadt, MD, FACG, AGAF, has disclosed that he has received fees for speaker’s bureau participation from Ferring, Merck, and Takeda; consulting fees from Ferring; and fees for advisory board participation from Ferring, Seres, and Takeda.
Kevin Garey, PharmD, MS

Professor and Chair
Department of Pharmacy Practice and Translational Research
University of Houston College of Pharmacy
Houston, Texas

Kevin Garey, PharmD, MS, has disclosed that he has received funds for research support from Acurx, Paratek, Seres, and Summit.

Staff

Courtney Smith, PharmD, MS
Courtney Smith, PharmD, MS, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
David C. Howard

Editorial Contributor

David Howard, BS in Pharmacy, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Kara Nyberg, PhD

Editorial Contributor

Kara Nyberg, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with Clostridioides difficile infections.

Goal

The goal of this activity is to improve the knowledge and competence of learners regarding strategies for diagnosis and management of Clostridioides difficile infections.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category l Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours.

Pharmacist Continuing Education

Credit Designation

CCO designates this continuing education activity for 2.0 contact hours (.02 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-096-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 50% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 05, 2022, through April 04, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Key Data on Therapeutic Options for Initial C difficile Infection (CDI) Episodes
  • CME
  • CE

Loading...
person default
Sahil Khanna, MBBS, MS
Program Director
person default
Teena Chopra, MD, MPH
Paul Feuerstadt, MD, FACG, AGAF
Kevin Garey, PharmD, MS
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Registered Nurses: 2.0 Nursing contact hours
Pharmacists: 2.0 contact hours (0.2 CEUs)
Released: April 5, 2022 Expiration: April 4, 2023

This program is divided into several short segments which you can step through using the Video Chapters menu.

Related Content

Clinical Care Options (CCO) expert analysis by Prof Stefan Zeuzem on new viral hepatitis data from EASL 2022, including HBV, HDV, and HCV

Stefan Zeuzem, MD Released: July 6, 2022

Expert selections of important viral hepatitis data from EASL 2022, including studies of patients with HBV, HDV (hepatitis delta virus), and HCV, from Clinical Care Options (CCO)

Tarik Asselah, MD, PhD Stefan Zeuzem, MD Released: July 6, 2022

Clinical Care Options (CCO) podcast with Prof Stefan Zeuzem on key viral hepatitis data from EASL 2022, including HBV, HDV (hepatitis delta), and HCV

Stefan Zeuzem, MD Released: July 6, 2022

Clinical Care Options (CCO) podcast with Dr Nancy Reau on exciting viral hepatitis data from EASL, including HBV, HDV (hepatitis delta), and HCV

Nancy Reau, MD Released: July 5, 2022

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings